Literature DB >> 20577760

Fibrodysplasia ossificans progressiva (FOP): watch the great toes!

Mutlu Kartal-Kaess1, Eileen M Shore, Meiqi Xu, Ludwig Schwering, Markus Uhl, Rudolf Korinthenberg, Charlotte Niemeyer, Frederick S Kaplan, Melchior Lauten.   

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder and the most disabling condition of heterotopic (extraskeletal) ossification in humans. Extraskeletal bone formation associated with inflammation preceding the osseous conversion usually begins in the first decade, predominantly in the head, neck, and shoulders. All patients have malformed great toes. Most patients have a spontaneous mutation of the ACVR1 gene. We report a 17-year-old girl with malformed great toes who had her first episode of heterotopic ossification and impaired mobility of the left hip at the age of 13 years. No inflammatory fibroproliferative masses preceded the onset of heterotopic ossification. Radiographic studies demonstrated myositis ossificans, but failure to associate the great toe malformation with heterotopic ossification led to a failure to diagnose FOP. She underwent repeated and unnecessary operative procedures to remove a recurrent lesion. FOP was finally suspected when the great toe malformation was correlated with the trauma-induced heterotopic ossification. Genetic analysis confirmed the presence of the classic FOP mutation (ACVR1 c.617G>A; R206H). This case highlights the importance of examining the great toes in anyone with heterotopic ossification. The association of malformations of the great toe with heterotopic ossification in all cases of classic FOP will lead to prompt clinical diagnosis and the prevention of iatrogenic harm.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20577760      PMCID: PMC4964587          DOI: 10.1007/s00431-010-1232-5

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  20 in total

1.  A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.

Authors:  Eileen M Shore; Meiqi Xu; George J Feldman; David A Fenstermacher; Tae-Joon Cho; In Ho Choi; J Michael Connor; Patricia Delai; David L Glaser; Martine LeMerrer; Rolf Morhart; John G Rogers; Roger Smith; James T Triffitt; J Andoni Urtizberea; Michael Zasloff; Matthew A Brown; Frederick S Kaplan
Journal:  Nat Genet       Date:  2006-04-23       Impact factor: 38.330

2.  Catastrophic falls in patients who have fibrodysplasia ossificans progressiva.

Authors:  D L Glaser; D M Rocke; F S Kaplan
Journal:  Clin Orthop Relat Res       Date:  1998-01       Impact factor: 4.176

Review 3.  Morphogen receptor genes and metamorphogenes: skeleton keys to metamorphosis.

Authors:  Frederick S Kaplan; Jay Groppe; Robert J Pignolo; Eileen M Shore
Journal:  Ann N Y Acad Sci       Date:  2007-09-13       Impact factor: 5.691

Review 4.  A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton.

Authors:  Frederick S Kaplan; David L Glaser; Robert J Pignolo; Eileen M Shore
Journal:  Expert Opin Biol Ther       Date:  2007-05       Impact factor: 4.388

5.  Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients.

Authors:  J M Connor; D A Evans
Journal:  J Bone Joint Surg Br       Date:  1982

6.  Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.

Authors:  Frederick S Kaplan; Meiqi Xu; Petra Seemann; J Michael Connor; David L Glaser; Liam Carroll; Patricia Delai; Elisabeth Fastnacht-Urban; Stephen J Forman; Gabriele Gillessen-Kaesbach; Julie Hoover-Fong; Bernhard Köster; Richard M Pauli; William Reardon; Syed-Adeel Zaidi; Michael Zasloff; Rolf Morhart; Stefan Mundlos; Jay Groppe; Eileen M Shore
Journal:  Hum Mutat       Date:  2009-03       Impact factor: 4.878

7.  Age- and joint-specific risk of initial heterotopic ossification in patients who have fibrodysplasia ossificans progressiva.

Authors:  D M Rocke; M Zasloff; J Peeper; R B Cohen; F S Kaplan
Journal:  Clin Orthop Relat Res       Date:  1994-04       Impact factor: 4.176

Review 8.  Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP).

Authors:  Eileen M Shore; Frederick S Kaplan
Journal:  Bone       Date:  2008-05-28       Impact factor: 4.398

Review 9.  Fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Martine Le Merrer; David L Glaser; Robert J Pignolo; Robert E Goldsby; Joseph A Kitterman; Jay Groppe; Eileen M Shore
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-03       Impact factor: 4.098

10.  BMP type I receptor inhibition reduces heterotopic [corrected] ossification.

Authors:  Paul B Yu; Donna Y Deng; Carol S Lai; Charles C Hong; Gregory D Cuny; Mary L Bouxsein; Deborah W Hong; Patrick M McManus; Takenobu Katagiri; Chetana Sachidanandan; Nobuhiro Kamiya; Tomokazu Fukuda; Yuji Mishina; Randall T Peterson; Kenneth D Bloch
Journal:  Nat Med       Date:  2008-11-30       Impact factor: 53.440

View more
  10 in total

1.  Are great toes always abnormal in patients with fibrodysplasia ossificans progressiva?

Authors:  Sumeet Gulshan Dua; Nilendu C Purandare
Journal:  Eur J Pediatr       Date:  2011-02-02       Impact factor: 3.183

2.  Clinical Utility Gene Card for: Fibrodysplasia ossificans progressiva.

Authors:  Nathalie Bravenboer; Dimitra Micha; James T Triffit; Alex N Bullock; Roberto Ravazollo; Renata Bocciardi; Maja di Rocco; J Coen Netelenbos; Peter Ten Dijke; Gonzalo Sánchez-Duffhues; Fred S Kaplan; Eileen M Shore; Robert J Pignolo; Petra Seemann; Francesc Ventura; Genevieve Beaujat; Elizabeth M W Eekhoff; Gerard Pals
Journal:  Eur J Hum Genet       Date:  2015-01-21       Impact factor: 4.246

3.  Myositis ossificans in children: a review.

Authors:  N K Sferopoulos; R Kotakidou; A S Petropoulos
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-03-09

4.  A Zebrafish Model of Human Fibrodysplasia Ossificans Progressiva.

Authors:  Melissa LaBonty; Nicholas Pray; Pamela C Yelick
Journal:  Zebrafish       Date:  2017-04-10       Impact factor: 1.985

Review 5.  Cellular and morphological aspects of fibrodysplasia ossificans progressiva. Lessons of formation, repair, and bone bioengineering.

Authors:  Anderson Martelli; Arnaldo Rodrigues Santos
Journal:  Organogenesis       Date:  2014-10-31       Impact factor: 2.500

6.  Injury of Adult Zebrafish Expressing Acvr1lQ204D Does Not Result in Heterotopic Ossification.

Authors:  Melissa LaBonty; Nicholas Pray; Pamela C Yelick
Journal:  Zebrafish       Date:  2018-09-05       Impact factor: 1.985

7.  Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases.

Authors:  Geneviève Baujat; Rémy Choquet; Stéphane Bouée; Viviane Jeanbat; Laurène Courouve; Amélie Ruel; Caroline Michot; Kim-Hanh Le Quan Sang; David Lapidus; Claude Messiaen; Paul Landais; Valérie Cormier-Daire
Journal:  Orphanet J Rare Dis       Date:  2017-06-30       Impact factor: 4.123

8.  Atypical Presentation of Fibrodysplasia Ossificans Progressiva: A Case Report and Review of Literature.

Authors:  Vivek Tiwari; Prateek Behera; Radha Sarawagi; Babu Mohammed Rafi; Saurabh Sahu; Hemanth Raj; Manish Rajpoot
Journal:  Cureus       Date:  2018-07-10

9.  Fibrodysplasia Ossificans Progressiva in a Four year Old Child.

Authors:  Mayur Kardile; Sidhartha Nayak; H S Nagaraja; Abani Kanta Mishra
Journal:  J Orthop Case Rep       Date:  2012 Apr-Jun

10.  When Limb Surgery Has Become the Only Life-Saving Therapy in FOP: A Case Report and Systematic Review of the Literature.

Authors:  Esmée Botman; Sanne Treurniet; Wouter D Lubbers; Lothar A Schwarte; Patrick R Schober; Louise Sabelis; Edgar J G Peters; Annelies van Schie; Ralph de Vries; Zvi Grunwald; Bernard J Smilde; Jakko A Nieuwenhuijzen; Marieke Visser; Dimitra Micha; Nathalie Bravenboer; J Coen Netelenbos; Bernd P Teunissen; Pim de Graaf; Pieter G H M Raijmakers; Jan Maerten Smit; Elisabeth M W Eekhoff
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-21       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.